Gilead Sciences (GILD) granted FDA approval for Quad pill, Stribild
Tweet
Share
E-mailGet Alerts GILD Hot Sheet
Join SI Premium – FREE
Gilead Sciences Inc. (Nasdaq: GILD) granted FDA approval for Quad pill, Stribild, for HIV.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU approves Gilead's Trodelvy combo with Keytruda for front-line TNBC
- EU grants Vanda's imsidolimab first orphan status for rare skin disease
- Spruce Biosciences BLA filing for rare disease drug on track for 2026
Create E-mail Alert Related Categories
FDA, Hot FDA NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
